QSAR - The Global Ophthalmic Pharmaceutical Market 2004-2009

The Global Ophthalmic Pharmaceutical Market 2004-2009
new visiongain report

Driven by demographic trends, such as an increasing aged population, the
global ophthalmic pharmaceutical market is set to become a serious growth
area experiencing a compound annual growth rate of 13.0% to 2009.
Visiongain's latest report, "The Global Ophthalmic Pharmaceutical Market
2004-2009", explains just how this market will
experience growth over the medium term future.

The world market is currently valued at $7.25bn and revenues are forecasts
to rise to over $14bn in 2009. Do you know what the drivers and restraints
of the market are? This report not only reveals these, but also details what
stratergies can be used to maxmise profits from the drivers and restraints?
Ensure your organisation is successful in this market by reserving your copy
of visiongain's report today.

According to the findings of the new 170+page report, visiongain reveals
that Glaucoma therapies are set to dominate the market over the forecast
period (2002-2009), accounting for almost 40% of market revenues by 2009.
Indeed, 2004 saw the first blockbuster drug of the market, used to treat
glaucoma.

Find out who are the major companies involved in the ophthalmic world market
today and in the future. And what R&D opportunities exist for 'new-comers'
to the ophthalmic pharmaceutical market.

In the process of providing a thorough evaluation of the market, the
visiongain Ophthalmics report focuses on the major therapeutic areas of the
market:

1. Glaucoma
2. AMD
3. Ocular Allergies
4. Dry Eye Syndrome
5. Ocular Infections
6. Ocular Inflammation

Do you know what the market values of these major therapeutic areas of the
ophthalmic world market are?

The report provides in-depth market analysis upon these areas, and
extensively identifies both prescription and OTC ophthalmic drugs by disease
and product type. The study also assess's the challenges faced by ophthalmic
companies, and what exciting market opportunites exist in this up- and-
coming therapeutic area.

Why You Must Buy This Report?

This report features over 50 tables, 30 graphs and charts, news, insights,
the latest developments and an in depth survey of the ophthalmics market
with up-to-date analysis. This report is a vital addition to gaining an
understanding of this highly profitable market sector and will give your
company 'the edge' on your competitiors. You can not afford to be without
this latest report from visiongain.

Below is the full able of contents:

The Global Ophthalmic Pharmaceutical Market 2004-2009
1. EExecutive Summary of Ophthalmics 2004
1.1 Abstract of Ophthalmics 2004
1.2 Introduction to Ophthalmics 2004
1.3 Summary of Ophthalmics 2004
Table 1.1 Total Worldwide Pharmaceutical Ophthalmics Market Forecast
($bn), 2002-2009
Graph 1.1 Total World Ophthalmic Pharmaceutical Market Value ($bn) 2002-2009
1.3.1 Top 5 Selling Ophthalmic Drugs in 2003
Table 1.2 Top 5 Selling Ophthalmic Drugs in 2003 and Their Manufacturers
1.3.2 The Top 3 Ophthalmic Drugs Revenue Forecasts ($m), 2002-2009
Table 1.3: Xaltan & Xalcom Revenue Forecast ($m), 2002-2009
Table 1.4: Cosopt Revenue Forecast ($m), 2002-2009
Table 1.5: Visudyne Revenue Forecast ($m), 2002-2009

2. The Ophthalmic Pharmaceutical Global Market
2.1 Ophthalmic Industry Structure
2.1.1 Ophthalmic Pharmaceuticals
2.1.2 Ophthalmic & Surgical Equipment
2.1.3 Vision Care
Chart 2.1: The Ophthalmic Industry by Area Sector Value, 2004
Table 2.1: Ophthalmic Pharmaceutical Industry Value, % Share of Total
Ophthalmology Industry and Growth % From Year to Year, 1999-2003
2.2 The Ophthalmic World Drug Market
Table 2.2: Total Worldwide Pharmaceutical Ophthalmics Market Forecast
($bn), 2002-2009
Graph 2.1 Total World Pharmaceutical Ophthalmics Market Value ($bn),
2002-2009
Graph 2.2 Total World Pharmaceutical Ophthalmics % Growth Rate, 2003-2009
Table 2.3 Worldwide Pharmaceutical Ophthalmics Market Forecast by
Disease ($bn), 2002-2009
Table 2. 4 Ophthalmic Disease Area Market Share %, 2003, 2006 and 2009
Chart 2.2 Ophthalmic Disease Area Market Share %, 2003
Chart 2.3 Ophthalmic Disease Area Market Share %, 2006
Chart 2.4 Ophthalmic Disease Area Market Share %, 2009
2.3 An Overview of the Eye
2.3.1 Anatomy of the Human Eye
Picture 2.1 Anatomy of the Human Eye
2.3.2 The Vision Process
2.4 The Leading Ophthalmic Diseases Profiles; What They Are & Their
Prevelance
2.4.1 Diabetic Retinopathy
2.4.2 Age Related Macular Degeneration (AMD)
2.4.3 Cataract
2.4.4 Glaucoma

Table 2.5: Eye Disease Prevelance and Projections for US Adults Aged Over 40
Table 2.6: Prevelance of Cataract, AMD and Open Angle Glaucoma Among
Adults 40 Years and Older in the US, 2004
Table 2.7: Prevelance of Diabetic Retionpathy Among Adults in the US, 2004
Table 2.8: Estimated Prevelance of Myopia and Hyperopia Among Adults
in the US, 2004
2.5 The 10 Major Selling Ophthalmic Drugs and Their Manufacturers
Table 2.9: Top 10 Selling Ophthalmic Drugs in 2003 and % Change in
Revenues From 2002
2.6 The Major Players of the Ophthalmic Pharmaceutical Market
Table 2.10: Top 10 Selling Ophthalmic Drug % Market Share, 2002 and 2003
Chart 2.5: Top 10 Selling Ophthalmic Drug Companies Market Share %, 2003
Chart 2.6: Top 10 Selling Ophthalmic Drug Companies Market Share %, 2002
Table 2.11: Top 10 Selling Ophthalmic Drugs Company Market Share %
Change From 2002 to 2003
Table 2.12: US Glaucoma Market Company Share %, 2000
Chart 2.7 US Glaucoma Market Company Share %, 2000
Table 2.13: Leading Ophthalmic Drug Companies by Market Share %, 2003
Chart 2.8:Total Ophthalmic Pharmaceutical Company Market Share %, 2003
2.7 Ophthalmic Market Drivers
2.7.1 Vision Loss From Eye Diseases Will Increase With the Aging
Population
2.7.2 New Drug Delivery Technology
Table 2.14 Advantages and Disadvantages of Ophthalmic Drug Delivery Routes
2.7.3 Back-of-the-Eye and Dry Eye Rich Pipelines
2.8 Market Restraints
2.8.1 Lack of Major Pharma Companies Involved
2.9 Strategic Options
2.10 The Economic Cost of Eye Diseases
2.11 Market Opportunities

3. Glaucoma Pharmaceuticals Market
3.1 An Introduction to Glaucoma: the 2nd Leading Cause of Blindness in the
US
Picture 3.1: Fluid Drainage of the Eye
3.1.1 Normal Fluid Drainage
3.1.2 The Cause of Glaucoma
3.1.3 Risk Factors for Glaucoma
3.2 Primary Open Angle Glaucoma
3.3 Closed Angle Glaucoma
3.4 Secondary Glaucoma
3.5 Normal Tension Glaucoma (NTG)
3.6 Pigmentary Glaucoma
3.7 Glaucoma Drug Treatments: An Overview
3.7.1 Increasing Aqueous Humour Outflow By Miotics,
Sympathomimetrics and Prostaglandins
3.7.2 Decreasing Aqueous Humour Production By Alpha Agonists,
Beta-Blockers and Carbonic Anhydrase Inhibitors
3.7.3 Reducing Aqueous Humour Volume By Hyperosmolars
3.8 Beta-Blockers Are the Principle Drug Treatment for Glaucoma
3.8.1 Beta-Blockers Described
Table 3.1 Current Beta Blockers Used to Treat Glaucoma, 2004
3.9 Prostaglandin Analogues May Threaten Beta-Blockers in Glaucoma Treatment
Table 3.2: Current Prostaglandin Analogues Used to Treat Glaucoma, 2004
3.9.1 The Success of Xaltan: The Most Significant Milestone in Glaucoma
3.9.2 Price: The Deciding Factor Between Prostaglandin Choice?
3.10 The Docosanoids As New Glaucoma Therapies
3.11 Miotics
Table 3.3: Current Miotics Used to Treat Glaucoma, 2004
3.12 Carbonic Anhydrase Inhibitors
Table 3.4: Current Carbonic Anhydrase Inhibitors Used to Treat Glaucoma,
2004
3.12.1 Trusopt
3.12.2 Azopt
3.12.3 Oral Carbonic Anhydrase Inhibitors
3.13 Alpha Agonists
Table 3.5: Current Alpha Agonists Used to Treat Glaucoma, 2004
3.13.1 Bromonidine
3.14 Hyperosmolars
3.15 Combination Therapies
Table 3.6 Summary of Glaucoma Drugs by Their Company, 2004
3.16 Glaucoma Meds Still Superior to Surgery
3.17 The Glaucoma World Market: A Dormant Giant
3.18 Prostaglandins Will Remain the Dominant Treatment for Glaucoma
Table 3.7: Total World Glaucoma Drug by Treatment Class Market Value
Forecast ($m), 2002-2009
Graph 3.1: Glaucoma World Market Value ($m), 2002-2009
Graph 3.2: Glaucoma World Market Growth (%), 2003-2009
Table 3.8: Total World Glaucoma Drug by Treatment Class Market Share
Forecast (%), 2002-2009
Chart 3.1: Glaucoma Drug by Class Market Share (%), 2003
Chart 3.2: Glaucoma Drug by Class Market Share (%), 2006
Chart 3.3: Glaucoma Drug by Class Market Share (%), 2009
3.19 Glaucoma Market Drivers
3.20 Glaucoma Market Restraints
3.21 Top 10 Selling Glaucoma Drugs in 2003 by Company
Table 3.9: Top 10 Selling Glaucoma Drugs in 2003 by Company ($m),
Including 2002 Sales & % Change from 2002 Sales
3.22 The Dominance of Merck of the 2004 Glaucoma Market
3.23 Market Share % of Top 10 Selling Glaucoma Drugs, 2003
Table 3.10: Market Share % of Top 10 Selling Glaucoma Drugs, 2003
Chart 3.4 Market Share % of the Top 10 Selling Glaucoma Drugs, 2003
3.24 Market Share % of the Top 10 Selling Glaucoma Drugs by Company
3.25 Company Market Share % of the Top 10 Selling Glaucoma Drugs, 2003
Table 3.11: Market Share % of the Top 10 Selling Drugs by Company
Chart 3.5: Company Market Share % of the Top 10 Selling Glaucoma Drugs, 2003
3.26 Pfizer Experienced A Massive Sales Plummet of Xaltan & Xalcom in 2003
Table 3.12: Xaltan and Xalcom Revenues ($m), 2001-2003
3.27 Glaucoma Pipeline Products
Table 3.13: Glaucoma Pipeline Products, 2004
3.28 Glaucoma Market Opportunities Are Plentiful

4. Age-Related Macular Degeneration (AMD) Pharmaceuticals Market
4.1 An Introduction to Wet and Dry AMD: The Leading Cause of Vision
Loss in the Senior Population
4.2 Risk Factors Associated with AMD
4.3 The Prevelance of AMD
4.4 Dry AMD: No Proven Treatments, Yet
4.5 Wet AMD: The Photosensitiser, Visudyne
4.6 Two New Drug Therapies for AMD In-Sight for 2005
4.7 Macugen and Retaane: Future Looks Good
4.8 AMD Prevention: Another Opportunity for Statins & Aspirin?
4.9 Market Demand of AMD Drug Therapies is Huge
4.10 Market Drivers
4.11 Market Restraints
4.12 Visudyne Revenues: An Eye Opener!
4.13 Visudyne Revenue Forecast ($m) 2002-2009
Table 4.1 Visudyne Revenue Forecast ($m) 2002-2009
Graph 4.1 Visudyne Revenue Forecast ($m), 2002-2009
Graph 4.2 Visudyne Growth Forecast (%), 2003-2009
Table 4.2 Total Worldwide AMD Drug Market Forecast ($bn). 2002-2009
Graph 4.3 Total World AMD Market Revenue Forecast ($bn), 2002-2009
Graph 4.4 Total World AMD Market Growth Forecast (%), 2003-2009
4.14 Pipeline AMD Products
Table 4.3 Pipeline AMD Products, 2004
4.15 AMD Market Opportunities

5. Ocular Allergies Pharmaceutical Market
5.1 Ocular Allergies: An Introduction
5.2 Seasonal & Perennial Allergic Conjunctivitis
5.2.1 Seasonal Allergic Conjunctivitis
5.2.2 Perennial Allergic Conjunctivitis
5.3 Giant Papillary Conjunctivitis
5.4 Vernal Keratoconjunctivitis
5.5 Atopic keratoconjunctivitis
5.6 The Drug Treatment of Ocular Allergies: An Overview
5.7 Antihistamines (H1-Receptor Antagonists)
Table 5.1: AntiHistamine, Combination and Co- Products, 2004
5.8 Mast Cell Stabilisers Are Not Effective for Several Weeks
Table 5.2: Mast Cell Stabiliser Products, 2004
5.9 Topical NSAIDs Have High Adverse Effect Incidence
Table 5.3: Topical NSAID Products, 2004
5.10 Corticosteroids Are Used With Caution
Table 5.4: Topical Corticosteroids Products, 2004
5.11 Dual/Multiple-Action Agents Have Poor Compliance
Table 5.5: Dual/ Multiple Action Antihistamine & Mast Cell Stabiliser
Products, 2004
Table 5.6: Summary of Products Used to Treat Ocular Allergies, 2004
5.12 Systemic v's Topical? The Argument Continues
5.13 Alcon's Patanol: The New Gold Standard of Ocular Allergies?
5.14 Market Drivers
5.15 Market Restraints
5.16 The Ocular Allergy World Market: Patanol by Alcon Reigns
Table 5.7 Total Worldwide Ocular Allergy Drug Market Forecast ($bn).
2002-2009
Graph 5.1 Total World Ocular Allergy Market Revenue Forecast ($bn),
2002-2009
Graph 5.2 Total World Ocular Allergy Market Growth Forecast (%), 2003-2009
5.17 Ocular Allergy Pipeline Products in 2004 is Dead!
5.18 Ocular Allergy Market Opportunities

6. Dry Eye Syndrome Pharmaceuticals Market
6.1 Introduction to Dry Eye Syndrome
6.2 The Causes of Dry Eye Syndrome
Chart 6.1: Causes of Dry Eye
6.3 High-Risk Populations for Dry Eye Syndrome
6.4 Dry Eye Syndrome Drug Treatments: An Overview
6.5 Drug Treatment of Dry Eye
6.6 Low Viscosity Artificial Tears
Table 6.1: Low Viscosity Artificial Tear Products Available, 2004
6.7 Moderate Viscosity Artificial Tears
Table 6.2: Moderate Viscosity Artificial Tear Products Available, 2004
6.8 High Viscosity Artificial Tears
Table 6.3: High Viscosity Artificial Tear Products Available, 2004
6.9 Gel Formulations
Table 6.4 Gel Formation Products Available, 2004
6.10 Lubricating Ointments
Table 6.5: Lubricating Ointment Products Available, 2004
6.11 Restasis (Cyclosporin) (Allergan)
6.12 How Does Restasis Work?
Table 6.6 Summary of Available Drug Therapies Used to Treat Dry Eye
Syndrome, 2004
6.13 Allergy and Dryness: Chicken or Egg?
6.14 Market Drivers
6.15 Market Restraints
6.16 The Dry Eye World Drug Market: Restasis Dominates
Table 6.7: Total World Dry Eye Market Revenue Forecast ($bn), 2002-2009
Graph 6.1: Total World Dry Eye Market Revenue Forecast ($bn), 2002-2009
Graph 6.2: Total World Dry Eye Market Growth Forecast (%), 2003-2009
6.17 Dry Eye Pipeline Products
Table 6.8 Dry Eye Pipeline Products, 2004
6.18 What are Secretagogues?
6.19 Market Opportunit ies in Dry Eye Syndrome

7. Ocular Infections Pharmaceuticals Market
7.1 Ocular Infections: An Overview
Table 7.1: List of Ocular Infections
7.2 Introduction to Hordeolum
7.2.1 External Hordeolum
7.2.2 Internal Hordeolum
7.3 Introduction to Blepatitis
7.4 Introduction to Conjunctivitis
7.5 Bacterial Conjunctivitis
7.6 Viral Conjunctivitis
7.7 Epidemic Keratoconjunctivitis
7.8 Pharyngoconjunctival Fever
7.9 Introduction to Keratitis
7.10 Herpes Simplex Keratitis
7.11 Bacterial Keratitis
7.12 Fungal Keratitis
7.13 Acanthamoeba Keratitis
7.14 The Drug Treatment of Ocular Infections
7.15.Topical Antibacterials: Fluroquinolones
7.15.1 4th Generation Fluroquinolones: A Revolution in Ocular
Infections Treatment
7.15.2 Problems Encountered With Fluroquinolones
7.15.3 Aminoglycosides: Tobrex by Alcon Performs Well
7.15.4 Erythromycin
7.15.5 Bacitracin
7.15.6 Polymyxin B Combinations
7.16 Systemic Antibacterials
7.17 Antivirals
Table 7.2 Systemic Antiviral Drug Products Available, 2004
7.18 Antifungals
Table 7.3 Antifungal Ophthalmic Drug Products Available, 2004
Table 7.4: Summary of Ocular Infection Drug Products Available, 2004
7.19 Market Drivers
7.20 Market Restraints
7.21 The World Ocular Infection Drug Market
Table 7.5: Total World Ocular Infection Drug Market Forecast ($bn),
2002-2009
Graph 7.1: Total World Ocular Infection Drug Market Revenue Forecast
($bn), 2002-2009
Graph 7.2: Total World Ocular Infection Drug Market Growth Forecast
(%), 2003-2009
7.22 Ocular AntiInfective Pipeline Products is Poor
Table 7.6: Ocular Infection Product Pipeline, 2004
7.23 Anti Infective Market Opportunities

8. Ocular Inflammatory Pharmaceuticals Market
8.1 Introduction to Ocular Inflammatory Disorders
8.2 Chalazion
8.3 Uvetitis
8.3.1 Anterior Uveitis
8.3.2 Intermediate Uveitis
8.3.3 Posterior Uveitis
8.4 Topical Corticosteroids Remain the Cornerstone of Ocular
Anti-Inflammatory Therapy
8.5 Topical Corticosteriods Available on the 2004 Market
Table 8.1 Topical Corticosteroid Drugs Available, 2004
8.5.1 Topical Steroids with Maximum Clinical Action
8.5.2 Topical Moderate-Strength Steroids
8.6 Corticosteroid Ointments
8.7 Oral Corticosteroids
8.8 Topical NSAIDS
8.9 COX-2 Inhibitors
Table 8.2 Summary of Ocular Inflammatory Products, 2004
8.10 Market Drivers
8.11 Market Restraints
8.12 The Ocular Inflammation World Drug Market
Table 8.2: Worldwide Pharmaceutical Ocular Inflammation Market
Forecast ($bn), 2002-2009
Graph 8.1: Total World Ocular Inflammation Drug Market Revenue
Forecast ($bn), 2002-2009
Graph 8.2: Total World Ocular Inflammation Drug Market Growth Forecast
(%), 2003-2009
8.13 Pipeline Inflammatory Products
8.14 Ocular Inflammatory Market Opportunities

9. Conclusion to Ophthalmics 2004
9.1 Conclusion to Ophthalmics 2004

List of Companies

Acadia, Acuity Pharmaceuticals, Advanced Vision Research, Akorn,
Alcon, Alimera Sciences, Allergan, Alza, Asah Glass, ASTA,
AstraZeneca, Aventis, Banyu Pharmaceuticals, Barr, Bausch & Lomb,
Baxter, Bio-Logic Aqua Technology, BMS, Celegene, Celltech, Chauvin,
CIBA Vision, Daiichi, Dista, Eyetech Pharmaceuticals, Fujisawa,
Genera, Genetech, Genvec, Gilead Sciences, Goldshield, GSK, Inflazyme
Pharmaceuticals, Insite, Inspire Pharmaceuticals, Isis
Pharmaceuticals, ISTA, Ixis, Janseen Pharmaceuticals, Karo Bio SIFI,
Medimmune, Merck, Miravant Medical Technology, Monarch, Nippon
Orgaeon, Norvartis, Novagali, Oculex, OcuSoft, Orhto-McNeil, Othera,
Oxigene, Pfizer, Pharmadix, Pliva, QLT, Restan, Roche, Sankyo, Santen,
Scherag, Schering-Plough, Senju, Sucampo Pharmaceuticals, Vista,
Wyeth.

-PRICING-

* Individual report pricing - single user copies of this report are
available for only GBP £1299
* Departmental copies (this entitles up to 5 individual users in your
department) of this report are available for only GBP £2599
* Allow your whole company to have access to this information for only
GBP £3999. Company-wide License allows your whole company access and
intranet use on CD Rom and .pdf.

Carriage is via FedEx:
USA - GBP£19.00 ASIA - GBP£25.00 Australia & NZ - GBP£25.00
EU GBP£23.00 Rest of Europe GBP£27.00
UK is sent next day delivery through Royal Mail.

-ORDERING-

To order simply contact Althea James mailto:althea.james:-:visiongaingroup.com

Should you have any questions or should you want to buy a copy please
let me know.

Kind Regards

Althea James
Visiongain
Tel: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
e-mail: mailto:althea.james#%#visiongaingroup.com

visiongain produce a range of timely business information material, if
you wish to receive information of new products, simply reply to this
email with ' New Products info' in the subject box.

By replying to this e-mail submitting your order for this product you
have agreed without limitation or qualification to be bound by and to
comply with these Terms and Conditions. You agree that you will not
fail to complete any transaction after submitting an order to purchase
a product or submit any order to purchase a product where you do not
intend to complete the transaction. You expressly acknowledge and
agree that visiongain Ltd can withhold any product as a result of
non-payment within the agreed credit terms of 30 days. Management
Reports will only be sent on receipt of payment. Confirm any
cancellations, prior to payment, in writing within one week and
receive a refund less a 10% + VAT service charge. Regrettably, no
refunds can be made for cancellations after one week.

To unsubscribe please reply with unsubscribe in the subject line.

Data protection:
Visiongain Ltd gathers and manages data in accordance with the Data
Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post,
telephone, fax or email, unless you state otherwise. If you wish your
details to be amended, please send your request to the Database
Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG.

Alternatively please reply withunsubscribe in the subject line. Please
allow approximately 7 days for your removal or update request, you
may receive additional pieces of communication from visiongain Ltd
during the transitional period, whilst the changes come into effect.
Received on 2001-09-23 - 22:08 GMT